ClinicalTrials.gg
Not yet recruitingNCT07476456SMART-SCDUpdated Mar 17, 2026

Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death

An observational study in Sudden Cardiac Death, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by China National Center for Cardiovascular Diseases · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
421
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.

Planned enrollment
12th of 15
421 · median 1,491
Started
2026
with 1 other
Observational
15 of 19
8 open now
Registered
17th of 19
by date
Lead sponsor
2 of 19
China National Center for Cardiovascular Diseases

Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one is the 12th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 17th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Death, Sudden, Cardiac with a site in China, or all of them as a file.
02

Study summary

This study is designed as a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death), which enrolls high-risk populations meeting the criteria for implantable cardioverter defibrillator (ICD) implantation.

The research focuses on the mechanistic association between skeletal muscle metabolic disorders and ventricular arrhythmia (VA) as well as sudden cardiac death (SCD), and aims to construct a "muscle-heart crosstalk" risk early warning system through integration of multimodal skeletal muscle data. We will systematically collect the following data:

Baseline handgrip strength measurement (Biomi-h500+X5); Functional diagnosis and phenotyping of sarcopenia conducted via the InBody 270 body composition analyzer; Non-contrast chest and abdominal computed tomography (CT) images (to extract novel imaging phenotypes including skeletal muscle density at the T12 vertebra level, intermuscular adipose tissue, subcutaneous adipose tissue, etc.); Serum biomarkers (GDF-8, Irisin, IL-6); Metabolomics data of skeletal muscle tissue from the ICD pocket (lipid/energy metabolism profiles detected via the UPLC-QTOF/MS platform); Ambulatory electrocardiographic data. All treatment and intervention regimens for patients will be independently formulated by clinicians in accordance with clinical guidelines, and the study itself does not involve any intervention measures. Prospective follow-up will be conducted at 3/6/12 months after ICD implantation. The primary endpoint is composite ventricular arrhythmia events (including SCD, appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia/ventricular fibrillation), and the secondary endpoint is all-cause mortality.

Through the above prospective cohort study, we will integrate multimodal data including novel CT imaging phenotypes of skeletal muscle, metabolomics profiles and functional phenotyping of sarcopenia using artificial intelligence techniques, so as to construct a precision prediction model for SCD, screen novel CT imaging phenotypes of sarcopenia and myogenic metabolites, and finally establish a generalizable SCD risk assessment tool and individualized intervention strategies.

Read the detailed description
  1. Study Design This is a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death). All treatments administered to enrolled patients will be independently determined by clinicians based on individual patient conditions. This study does not involve any interventional therapeutic measures, and only collects multimodal data via observational procedures.
  2. Study Population Study subjects are patients receiving implantable cardioverter defibrillator (ICD) implantation at [Name of Hospital] who meet all inclusion criteria and do not meet any of the exclusion criteria.

    Inclusion Criteria:

    Undergoing first-time ICD implantation (including cardiac resynchronization therapy defibrillator, CRT-D implantation); Completed multi-dimensional sarcopenia assessment at baseline; Willing to receive prospective follow-up and signed the informed consent form (ICF).

    Exclusion Criteria:

    History of valvular heart disease (e.g., mitral stenosis, history of heart valve replacement or valvuloplasty, etc.); Implanted ICD type is subcutaneous ICD (S-ICD) or extra-vascular ICD (EV-ICD); Concomitant comorbidities affecting muscle metabolism, such as malignant tumors, severe liver or kidney disease, etc.

  3. Study Duration Enrollment period: Planned to complete enrollment of all subjects within 12 months after study initiation.

    Total study duration: Approximately 2 years, broken down as follows: preparation and finalization of clinical trial documents (including study protocol, investigator's brochure, informed consent form, case report form) takes \~2 months; ethical review approval takes \~3 months; enrollment period is 9 months; follow-up period is 12 months; data management, statistical analysis and report writing take \~2-3 months.

  4. Sample Size A total of 421 subjects are planned to be enrolled.
  5. Skeletal Muscle (Sarcopenia) Assessment Indicators Routine assessment: Muscle strength is measured using a handgrip dynamometer from Biometrics Ltd., UK (Biomi-h500+X5). Skeletal muscle mass is measured using a multi-frequency body composition analyzer (InBody 270, Biospace Co., Ltd., Korea) in the Rehabilitation Center of [Name of Hospital]. Sarcopenia diagnosis and phenotyping are performed combining the above two indicators.

    Imaging phenotypes: Based on preoperative non-contrast chest and abdominal computed tomography (CT) images, muscle imaging features at the level of the 12th thoracic vertebra (T12) are collected, including area and density of subcutaneous adipose tissue (SAT), area and density of intermuscular adipose tissue (IMAT), and skeletal muscle density (SMD), etc.

    **Biomarkers: Baseline blood and urine samples are collected to analyze sarcopenia-related factors including growth differentiation factor 8 (GDF-8), myokine irisin, and interleukin-6 (IL-6).

    Metabolomics analysis: Approximately 20 mg of skeletal muscle tissue at the ICD pocket site is collected synchronously during ICD implantation for metabolomics analysis. Subjects are divided into 4 groups: sarcopenia+VA, non-sarcopenia+VA, sarcopenia+non-VA, non-sarcopenia+non-VA. Targeted detection of myogenic metabolites will be performed: we plan to enroll 30 subjects per group to explore differential metabolites in the exploratory phase, then expand the sample size for validation. The ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) platform will be used to focus on detecting abnormalities in lipid and energy metabolism.

  6. Follow-up Nodes and Content Follow-up time points: Prospective follow-up will be conducted at 3 months, 6 months, and 12 months after ICD implantation.

Follow-up content:

Primary endpoint: Composite ventricular arrhythmia (VA) events, including sudden cardiac death (SCD), appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia (VT)/ventricular fibrillation (VF).

Secondary endpoint: All-cause mortality.

03

Conditions studied

  • Sudden Cardiac Death

Keywords

  • Sarcopenia
  • Skeletal Muscle Metabolism
  • Ventricular Arrhythmia
  • Multimodal Predictive Model
  • Sudden cardiac death
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients receiving implantable cardioverter defibrillator (ICD) implantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing first-time ICD implantation (including cardiac resynchronization therapy defibrillator, CRT-D implantation);
  • Completed multi-dimensional sarcopenia assessment at baseline;
  • Willing to receive prospective follow-up and signed the form (ICF)

Exclusion criteria

Exclusion Criteria:

  • History of valvular heart disease (e.g., mitral stenosis, history of heart valve replacement or valvuloplasty, etc.);
  • Implanted ICD type is subcutaneous ICD (S-ICD) or extra-vascular ICD (EV-ICD);
  • Concomitant comorbidities affecting muscle metabolism, such as malignant tumors, severe liver or kidney disease, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
421 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Composite ventricular arrhythmia (VA) events

    including sudden cardiac death (SCD), appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia (VT)/ventricular fibrillation (VF)

    Time frame: 12 months

Secondary outcomes

  1. All-cause mortality

    All deaths caused by various causes

    Time frame: 12 months

07

Study locations

1 site
  • Beilishi Road 167
    Beijing, Beijing Municipality 100037, China
    • NCCD · Contactncrc@fuwai.com · 01088822295
    • Xiaoyao Li, PhD · Principal investigator
08

References and documents

Publications

  • Damluji AA, Alfaraidhy M, AlHajri N, Rohant NN, Kumar M, Al Malouf C, Bahrainy S, Ji Kwak M, Batchelor WB, Forman DE, Rich MW, Kirkpatrick J, Krishnaswami A, Alexander KP, Gerstenblith G, Cawthon P, deFilippi CR, Goyal P. Sarcopenia and Cardiovascular Diseases. Circulation. 2023 May 16;147(20):1534-1553. doi: 10.1161/CIRCULATIONAHA.123.064071. Epub 2023 May 15. PubMed 37186680 ↗
  • Sayer AA, Cooper R, Arai H, Cawthon PM, Ntsama Essomba MJ, Fielding RA, Grounds MD, Witham MD, Cruz-Jentoft AJ. Sarcopenia. Nat Rev Dis Primers. 2024 Sep 19;10(1):68. doi: 10.1038/s41572-024-00550-w. PubMed 39300120 ↗
  • Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262. No abstract available. PubMed 36017572 ↗

Individual participant data

Plan to share: Undecided — The datasets generated and analysed during the current study can be found at Fuwai Hospital but not publicly available due to related regulations. Data and materials are however available from the authors upon reasonable request and with permission of research group.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jun 2027, 15 months later.

Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 15 months is below that.

Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Mar 16, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476456
Responsible party
Xiaoyao Li (Arrhythmia Center Attending Physician, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Mar 17, 2026
Start date
Mar 16, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Mar 17, 2026

Study contacts

Xiaoyao Li, PhD
Contact
fwlxy2015@163.com
+86 01088322295

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion